en

PRODUCT DETAIL

Apremilast Krka d.d. 30 mg filmom obalené tablety

Code 7301E
MA number 59/0206/24-S
Product Form: tbl flm 56x30 mg (blis.OPA/Al/PVC//Al)
MA Status: R - Valid Marketing Authorisation
Type of procedure: Decentralised
MAH, country: KRKA, d.d., Novo mesto, Slovenia
Therapeutic Class: 59 - IMMUNOPRAEPARATA
ATC:
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L04 Immunosuppressants
L04A Immunosuppressants
L04AA Selective immunosuppressants
L04AA32 Apremilast
Shelf life: 24
Container: blister OPA/Al/PVC/Al
Route of admin.: Oral use
Prescription Status: Medicinal product subject to restricted medical prescription.
Legal basis: Article 10(1) generic application
MA issued: 28.08.2024
Validity: 28.08.2029
PIL: PIL_Apremilast Krka d.d._08.2024.pdf  
SPC: SPC_Apremilast Krka d.d._08.2024.pdf  
Dokument: VHS_SK_H_0306_0307_0309_001-002_DC_Apremilast Krka d.d.Apremilast Krka Apremilast HCS_PAR.pdf  
Dokument: VHS_súhrn_SK_H_0306_0307_0309_001-002_DC_Apremilast Krka d.d.,Apremilast Krka, Apremilast HCS_Summary PAR.pdf  
Safety feature Yes
Data update: 09.09.2024
eu-flag.png sk-flag.png